Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurobo Pharmaceuticals Inc (NQ: NRBO )

2.370 +0.020 (+0.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurobo Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for November 14th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
NeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap Event
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024
NRBO stock results show that NeuroBo Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024
NRBO stock results show that NeuroBo Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The Top 3 Stocks to Watch This Week
There are three stocks to watch this week as they experienced significant price movements worth your attention. 
Via InvestorPlace
Dow Jumps 250 Points; Honeywell Issues Weak Forecast
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow traded up 0.66% to 38,403.91 while the NASDAQ rose 1.01% to 15,316.80. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
Stocks Rise Amid Flood Of Economic Data
Stocks are comfortably higher this afternoon, as investors continue to unpack the Fed's rate decision as well as this morning's jobs data. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.23% to 38,238.99 while the NASDAQ rose 0.54% to 15,245.46. The S&P 500 also rose,... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) is One of Thursday Morning’s Most Active Stocks
Via Investor Brand Network
Exposures COVID-19
Why Obesity-Drug Maker NeuroBo Stock Is Trading Higher
NeuroBo announced that the FDA has cleared its IND application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon... 
Via Benzinga
Exposures Product Safety
Nasdaq Surges 100 Points; US Jobless Claims Increase To 224,000
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.14% to 38,204.88 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Clinical-Stage Biotech Firm NeuroBo Shares Today?
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares are trading lower in Friday's premarket session after ending Thursday's session with a whopping 21.2% gain. 
Via Benzinga
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for December 14th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market. 
Via Benzinga
NeuroBo Pharma Says Its Weight Loss Candidate Outperforms Major Competitors in Preclinical Obesity Study
NeuroBo Pharmaceuticals Inc (NASDAQ: NRBO) says its DA-1726, a novel oxyntomodulin analog functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, had been shown to elicit... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 41 companies set new 52-week lows. 
Via Benzinga
Why LogicMark Shares Are Trading Lower By Around 25%; Here Are 20 Stocks Moving Premarket
Gainers Axcella Health Inc. (NASDAQ: AXLA) rose 71.7% to $0.7450 in pre-market trading after the company reported regulatory path to registration of AXA1125 for long COVID-19 fatigue. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.